Results 31 to 40 of about 6,850 (200)

Treatment of ocular myasthenia with corticotrophin [PDF]

Journal of Neurology, Neurosurgery & Psychiatry, 1971
Nine patients with severe myasthenia gravis, including ocular symptoms, who did not respond to anticholinesterase therapy were given prolonged courses of corticotrophin. In all patients except one there was an initial deterioration, sometimes necessitating assisted respiration, followed by a marked improvement which persisted for many weeks and ...
F B, Gibberd, F, Navab, C L, Smith
openaire   +2 more sources

Efficacy and Safety of Guselkumab in Participants With Active Psoriatic Arthritis After Inadequate Response to One Prior Tumor Necrosis Factor Inhibitor: Week‐24 Results of a Phase 3, Randomized, Placebo‐Controlled Study

Arthritis &Rheumatology, EarlyView.
Objective To evaluate the efficacy and safety of guselkumab, an interleukin‐23p19 subunit inhibitor, in participants with active psoriatic arthritis (PsA) and inadequate response (inadequate efficacy and/or intolerance) to one prior tumor necrosis factor (TNF) inhibitor.
Alexis Ogdie, Joseph F. Merola, Philip J. Mease, Christopher T. Ritchlin, Jose U. Scher, Kimberly Parnell Lafferty, Daphne Chan, Soumya D. Chakravarty, Wayne Langholff, Yanli Wang, Jie Shao, Yevgeniy Krol, Alice B. Gottlieb   +12 more
wiley   +1 more source

Trauma-Induced Double-Seronegative Ocular Myasthenia Gravis: A Case Report

Journal of Rawalpindi Medical College
We present here a 12-year-old child who presented with complaints of blurring of vision and drooping of the left upper eyelid for the past 4 years, which started 1 month after he encountered blunt trauma to the left-sided orbital region.
Mohammad Ali Khalid, Muhammad Jawad Awan, Ambreen Gull, Nida Hafeez, Bushra Ali, Fuad Ahmad Khan Niazi   +5 more
doaj   +1 more source

Treatment‐Related Adverse Events and Health‐Related Quality of Life Associated With Immune Checkpoint Inhibitor Treatment for Mucosal Head and Neck Squamous Cell Carcinoma: A Scoping Review

Head &Neck, EarlyView.
ABSTRACT Background Supportive care needs of patients receiving immune checkpoint inhibitors (ICIs) for head and neck squamous cell carcinoma (HNSCC) are ill‐defined. Hence, known treatment‐related adverse events (TRAEs) and health‐related quality of life (HRQoL) associated with ICI treatment for HNSCC were examined to inform future supportive care ...
N. D. O'Donnell, E. C. Ward, L. R. Wishart, R. Perera, C. Barrett, K. A. Edmiston, E. Mitchell, A. Pigott, R. Pitt, K. Russell, B. A. Chan, R. Ladwa   +11 more
wiley   +1 more source

Evaluation of DNA/Chromosome Integrity and Cell Death in Human Metabolically Noncompetent and Competent Cells Exposed to N′‐(3,5‐Difluorobenzylidene)Pyridine‐4‐Carbohydrazide

Journal of Applied Toxicology, EarlyView.
ABSTRACT The N‐acylhydrazone scaffold is recognized as a privileged structure for the design of bioactive substances with increasing applications in medicinal chemistry research. Ensuring the safety of newly developed molecules is a critical step for both human health and environmental protection. Accordingly, this study aimed to evaluate the cytotoxic
Larissa Ribeiro Canuto Santos, Jéssica Natalia Barbosa de Almeida, Camila Cavalleiro Frias, Wanda Pereira Almeida, Edson Luis Maistro   +4 more
wiley   +1 more source

Treatment Preferences of Patients With Myasthenia Gravis: A Qualitative Study

Muscle &Nerve, EarlyView.
ABSTRACT Introduction/Aims The burden of myasthenia gravis (MG) is often underestimated, and studies usually focus on the symptom burden. However, treatment‐related adverse events also contribute to patients' burdens and affect their treatment decisions.
Meg Mendoza, Elena Wolff, Michael Chou, Vera Bril, Hans Katzberg, Ahmed Bayoumi, Carolina Barnett‐Tapia   +6 more
wiley   +1 more source

IgG Subclass (IgG1‐4) and IgA Autoantibody Profiles Against Muscle‐Specific Kinase in a Greek Cohort

Muscle &Nerve, EarlyView.
ABSTRACT Introduction/Aims Muscle‐specific kinase myasthenia gravis (MuSK‐MG) is an autoimmune neuromuscular disorder predominantly mediated by IgG4 autoantibodies disrupting MuSK signaling. The contribution of other isotypes remains incompletely defined. We characterized the serological profile of a Greek cohort of MuSK‐MG patients.
Sofia‐Natsοuko Gkotzamani, Maria Pechlivanidou, Francisca Faber, Cansu Elmas, Vasiliki Zouvelou, Elisabeth Chroni, Dimitrios Tzanetakos, Maria Kourouvani, Marlene Wolfsgruber, Ioannis Zaganas, Dimitra Kolovou, Michael Rentzos, Ariadne Daponte, Maria Chondrogiorgi, Spyridon Konitsiotis, Georgios Nicolaou, Stavroula Salakou, Sotirios Giannopoulos, Konstandinos Lazaridis, Georgios Tsivgoulis, Socrates Tzartos, Inga Koneczny, John S. Tzartos   +22 more
wiley   +1 more source

Diagnostic accuracy and clinical utility of bed side tests versus laboratory tests in the diagnosis of ocular myasthenia

Indian Journal of Ophthalmology, 2022
Purpose: To assess the diagnostic accuracy of forced eyelid closure test (FECT), ice pack test (IPT), repetitive nerve stimulation test (RNS), and acetylcholine receptor (AchR) antibody test in patients with suspected ocular myasthenia.
PriyaSivakumar, ShivrajTagare, MaheshKumar   +2 more
doaj   +1 more source

Myasthenia Gravis and Thymoma

Muscle &Nerve, EarlyView.
ABSTRACT Thymoma is the most common tumor of the anterior mediastinum. Approximately 20%–30% of patients with a thymoma develop myasthenia gravis (MG), and an additional one third may possess positive acetylcholine receptor (AChR) antibodies without MG.
Benjamin Claytor, Lukas Delasos, Daniel P. Raymond, Erik Seroogy, Jason Lempel, Yuebing Li   +5 more
wiley   +1 more source

Botulinum toxin use in patients with neurological disorders: A U.S.‐based claims database analysis

PM&R, EarlyView.
Abstract Background and Objective Real‐world evidence describing long‐term persistency with botulinum toxin (BoNT) therapy is limited. We assessed treatment patterns and persistency with BoNT in clinical practice over 2 years. Design Retrospective, longitudinal, claims database analysis. Setting Medical claims data from the Merative MarketScan database
David M. Simpson, Jonathan Bouchard, Simon Page, Seth Goldfarb, Atul T. Patel   +4 more
wiley   +1 more source